Form 4: Edgewell Grants RSEs to Chief Accounting Officer

Edgewell Personal Care Co. granted 3,586 Restricted Stock Equivalents to Chief Accounting Officer John M. Dunham, vesting over three years.

Summary

• John M. Dunham, Chief Accounting Officer of Edgewell Personal Care Co. (EPC), was granted 3,586 Restricted Stock Equivalents (RSEs).
• The transaction date for this grant was November 14, 2025.
• The RSEs have a grant price of $0.
• One-third of the RSEs will vest and convert into shares of Edgewell common stock on November 14, 2026, November 14, 2027, and November 14, 2028, respectively.
• Vesting is contingent upon Mr. Dunham's continued employment on the specified dates.
• A portion or all RSEs may also vest upon death, disability, change in control, or certain termination events.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard executive compensation practice aimed at retention and aligning management interests with shareholders, without indicating any immediate negative operational or financial issues.

Positives

• The grant of Restricted Stock Equivalents serves as an incentive for the Chief Accounting Officer, aligning his interests with long-term shareholder value.
• This compensation structure is a common tool for executive retention, encouraging continued service to the company.

Negatives

• The conversion of RSEs into common stock upon vesting will result in a minor dilution of existing shareholder equity.

Risks

• The vesting of the Restricted Stock Equivalents is contingent on the reporting person's continued employment, meaning the full benefit is not guaranteed if employment ceases prematurely under certain conditions.

Future Outlook

The grant of Restricted Stock Equivalents indicates a strategy to retain key executive talent and align management incentives with the company's long-term performance through equity ownership, contingent on continued employment.

Industry Context

The grant of Restricted Stock Equivalents is a standard practice in executive compensation across various industries, including personal care, to incentivize and retain key management personnel. This type of equity award aligns executive interests with shareholder value creation over a multi-year vesting period.

Comparison to Industry Standards

• The use of Restricted Stock Equivalents with a multi-year vesting schedule is a common and widely accepted form of long-term incentive compensation for executives in publicly traded companies, comparable to practices at peers like Procter & Gamble (PG), Kimberly-Clark (KMB), and Colgate-Palmolive (CL).
• The grant price of $0 for RSEs is typical, as these awards represent a right to receive shares of common stock, often without an exercise price, upon meeting specific vesting conditions.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting, but the grant aims to align executive performance with shareholder value.
• Employees (specifically John M. Dunham): Provides a significant long-term incentive and retention mechanism, contingent on continued employment.

Next Steps

• The RSEs will vest in three equal annual installments on November 14, 2026, November 14, 2027, and November 14, 2028, provided employment conditions are met.

Key Dates

Keywords

Edgewell Personal Care, EPC, Restricted Stock Equivalents, RSEs, Executive Compensation, Insider Transaction, John M. Dunham, Chief Accounting Officer, Stock Grant, Vesting